Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH), MASH, and liver-directed metabolic therapy.
An open-label RCT finds 24 g/day fibre cereal improves the FIB-4 fibrosis index and HbA1c in type 2 diabetes with fatty liver, without weight change. PICO summary and commentary.
In a phase 2 trial, the antisense DGAT2 inhibitor ION224 met the primary histological endpoint in MASH with fibrosis at week 51, though benefit remains preliminary and per-protocol. PICO summary and expert commentary.
An early-phase trial of the GLP-1/FGF21 dual agonist HEC88473 reported dose-proportional liver fat reduction and improved glycaemic control over 5 weeks in patients with MASLD and type 2 diabetes. PICO summary and expert commentary.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
A small randomized trial finds baseline IL-1β in mononuclear cells predicts the degree of MASLD improvement after weight loss in obesity with prediabetes or early type 2 diabetes. PICO summary and expert commentary.
A small randomised trial finding that weight loss reduced IL-1β and MASLD comparably with liraglutide or lifestyle, and that baseline IL-1β predicted the extent of MASLD improvement. PICO summary and expert commentary.
A multicentre randomised trial found dapagliflozin 10 mg daily for 48 weeks improved biopsy-confirmed MASH without worsening fibrosis in more patients than placebo. PICO summary and expert commentary.
A 24-week open-label randomised trial testing pioglitazone plus empagliflozin versus monotherapy for fatty liver in type 2 diabetes. PICO summary and expert commentary.
A small secondary analysis of the EDICT randomised trial reports that initial triple therapy was associated with slower carotid intima-media thickness progression and lower liver fat than sequential add-on therapy at matched glycaemic control. PICO summary and expert commentary.
An exploratory randomised trial of an 880 kcal/day total diet replacement programme in 17 adults with compensated MASLD cirrhosis found safe weight loss and reduced liver fat, but cannot confirm efficacy. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
